Traders should monitor FILSPARI's commercial uptake in FSGS, as the expanded indication significantly increases the addressable market and royalty stream for Ligand; the 9% royalty on a growing sales base could drive outsized revenue growth if adoption accelerates.
LGND drugs
LGND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $232.34entry
- T+1 · 7mo ago −3.12%α −3.90% · $225.09
- T+5 · 7mo ago −2.44%α −3.83% · $226.67
- T+20 · 6mo ago −5.10%α −11.40% · $220.48
- T+60 · 4mo ago +38.85%α +30.33% · $322.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, marking the first approved therapy for this condition. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI, which expands its commercial potential beyond IgA nephropathy and positions it as a key driver of future royalty growth.
Key Facts
- FDA approved FILSPARI for FSGS in patients aged 8+ without nephrotic syndrome, the first and only approved treatment for this indication.
- Ligand receives a 9% royalty on worldwide net sales of FILSPARI, which is already the most prescribed FDA-approved drug for IgA nephropathy.
- Phase 3 DUPLEX study showed a 46% reduction in proteinuria overall and 48% in non-nephrotic syndrome patients, with statistically significant results.
- Addressable U.S. population estimated at over 30,000 patients with FSGS without nephrotic syndrome.
- FILSPARI has a dual mechanism targeting endothelin A and angiotensin II receptors, offering kidney protection.
Financial Impact
High incremental royalty revenue potential from expanded indication; FILSPARI now addresses a second rare kidney disease with significant unmet need.
Risk Factors
- Commercial execution risk: Market penetration and reimbursement for the new FSGS indication may lag expectations.
- Regulatory and clinical risk: Future safety findings or label restrictions could limit use.
- Competition risk: Emerging therapies for FSGS could challenge FILSPARI's dominance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273192 |
Track record
29 reports on LGND
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers